Compare OVID & PGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OVID | PGP |
|---|---|---|
| Founded | 2014 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 117.5M | 102.9M |
| IPO Year | 2017 | N/A |
| Metric | OVID | PGP |
|---|---|---|
| Price | $1.62 | $9.35 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $3.40 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 28.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.84% |
| EPS Growth | ★ 3.90 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $566,000.00 | N/A |
| Revenue This Year | $1,077.56 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.24 | $6.56 |
| 52 Week High | $2.01 | $9.41 |
| Indicator | OVID | PGP |
|---|---|---|
| Relative Strength Index (RSI) | 53.68 | 60.32 |
| Support Level | $1.43 | $9.20 |
| Resistance Level | $1.70 | $9.41 |
| Average True Range (ATR) | 0.10 | 0.08 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 82.26 | 86.05 |
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
PIMCO Global Stocksplus & Income Fund is a closed-end management investment company. The objective of the fund is to seek a total return comprised of current income, current gains, and long-term capital appreciation. The fund invests a majority of the fund's net assets in a combination of securities and instruments that provide exposure to stocks and or produce income.